A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Launched by ELI LILLY AND COMPANY · Nov 21, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called LY900038, is looking to find safe and effective ways to help adults with obesity or who are overweight manage their weight long-term. It is a Phase-2 study, which means it is testing new treatments to see how well they work. The trial has a flexible structure that allows different treatments to be tested independently. If you are between the ages of 18 and 75, have a body mass index (BMI) of 27 or higher, and have maintained a stable weight for the past three months, you might be eligible to participate.
If you join the trial, you will have the chance to try one of the new weight management interventions while being closely monitored by healthcare professionals. However, there are some important factors that could prevent you from participating, such as having certain serious health conditions or previous obesity surgeries. Overall, this trial aims to gather information that could lead to better options for managing weight for people struggling with obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have a body mass index (BMI)
- • ≥30 kilogram/square meter (kg/m²), or
- • ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity
- • Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss.
- Exclusion Criteria:
- • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening.
- • Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
- • Have poorly controlled hypertension.
- • Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
- * Have any of the following cardiovascular conditions within 3 months prior to screening:
- • acute myocardial infarction
- • cerebrovascular accident (stroke)
- • unstable angina, or
- • hospitalization due to congestive heart failure.
- • Have a history of symptomatic gallbladder disease within the past 2 years.
- • Have a lifetime history of suicide attempts.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Walnut Creek, California, United States
Amherst, New York, United States
Phoenix, Arizona, United States
New Port Richey, Florida, United States
Louisville, Kentucky, United States
Stamford, Connecticut, United States
Rolling Hills Estates, California, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Skokie, Illinois, United States
Topeka, Kansas, United States
Phoenix, Arizona, United States
West Des Moines, Iowa, United States
Saint Peters, Missouri, United States
Cincinnati, Ohio, United States
Las Vegas, Nevada, United States
Danville, Virginia, United States
Las Vegas, Nevada, United States
Monroe, North Carolina, United States
East Syracuse, New York, United States
Dallas, Texas, United States
Miami, Florida, United States
Houston, Texas, United States
Honolulu, Hawaii, United States
Huntington Park, California, United States
Greensboro, North Carolina, United States
Port Jefferson Station, New York, United States
Huntington Park, California, United States
Greenbrae, California, United States
Troy, Michigan, United States
Springfield, Missouri, United States
Greenville, South Carolina, United States
Hialeah, Florida, United States
Chicago, Illinois, United States
Fleming Island, Florida, United States
Morehead City, North Carolina, United States
Winter Park, Florida, United States
San Antonio, Texas, United States
Mesa, Arizona, United States
East Syracuse, New York, United States
Weslaco, Texas, United States
Scottsdale, Arizona, United States
Cincinnati, Ohio, United States
San Antonio, Texas, United States
Dallas, Texas, United States
Chicago, Illinois, United States
Ammon, Idaho, United States
The Villages, Florida, United States
Rochester, New York, United States
Wenatchee, Washington, United States
New Bern, North Carolina, United States
Springfield, Missouri, United States
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Ciudad Autonoma De Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Tucson, Arizona, United States
Needham, Massachusetts, United States
Southfield, Michigan, United States
New Bedford, Massachusetts, United States
Houston, Texas, United States
Austin, Texas, United States
Orlando, Florida, United States
Winter Park, Florida, United States
Topeka, Kansas, United States
Ciudad Autónoma De Buenos Aires, , Argentina
Stamford, Connecticut, United States
Chandler, Arizona, United States
New Bern, North Carolina, United States
Chandler, Arizona, India
Ciudad Autonoma De Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Honolulu, Hawaii, United States
Dallas, Texas, United States
St. Peters, Missouri, United States
West Des Moines, Iowa, United States
Buenos Aires, , Argentina
Ciudad Autonoma De Buenos Aires, , Argentina
Ciudad Autonoma De Buenos Aires, , Argentina
Patients applied
KC
KG

JP
AB
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4550 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported